KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Retained Earnings: 2009-2024

Historic Retained Earnings for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $31.7 billion.

  • Regeneron Pharmaceuticals' Retained Earnings rose 13.95% to $35.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0 billion, marking a year-over-year increase of 13.95%. This contributed to the annual value of $31.7 billion for FY2024, which is 16.19% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Retained Earnings of $31.7 billion as of FY2024, which was up 16.19% from $27.3 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' 5-year Retained Earnings high stood at $31.7 billion for FY2024, and its period low was $10.9 billion during FY2020.
  • For the 3-year period, Regeneron Pharmaceuticals' Retained Earnings averaged around $27.4 billion, with its median value being $27.3 billion (2023).
  • Data for Regeneron Pharmaceuticals' Retained Earnings shows a peak YoY spiked of 74.13% (in 2021) over the last 5 years.
  • Regeneron Pharmaceuticals' Retained Earnings (Yearly) stood at $10.9 billion in 2020, then spiked by 74.13% to $19.0 billion in 2021, then increased by 22.87% to $23.3 billion in 2022, then climbed by 16.96% to $27.3 billion in 2023, then increased by 16.19% to $31.7 billion in 2024.